U.S. MarketsSeptember 30 at 08:15 AM

Merck's (MRK) tulisokibart met primary and key secondary endpoints in Phase 2b study in patients with moderate to severe hidradenitis suppurativa

StockNow breaking-news AI analysis

The headline reports positive Phase 2b endpoint results for tulisokibart, but the retrieved record lacks the article body and details needed to assess the findings.

1 stocks

MRKMerck & Co., Inc.$148.98Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

Israeli press reports growing assessments that the incident aboard the Flydubai plane was a terrorist attack, Al Jazeera adds; reports suggest the co-pilot who stabbed the other pilot was of Omani origin

Geopolitics

Senior source says mediators are working to return negotiations to a broader track that includes the nuclear issue, Al Hadath reports

Commodities